News Posts
Giving stem cells a kick in vitro with stromal derived factor-1
Cincinnati, OH - Commercialization of stem cell therapy is difficult since sometimes one doesn't really know what the product is. Additionally, there could be many products that are developed that are used in the implimentation of a single therapy. A current publication (Pasha et al. Preconditioning Enhances Cell Survival and Differentiation of Stem Cells during Transplantation in...Monday November 19th, 2007 @ 15:30:37 EST
Medistem Publishes Menstrual Stem Cell Discovery
Medistem Announces Discovery of Novel Stem Cell Population in Menstrual Blood: Endometrial Regenerative Cells (ERC) Cells Produce 100,000 Times the Number of Growth Factors Found in Cord Blood SCOTTSDALE, AZ--(Marketwire - November 15, 2007) - Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) in collaboration with researchers from the University of Western Ontario, University of...Sunday November 18th, 2007 @ 15:04:46 EST
Medistem (mdsm.ob) Discovers Menstrual Blood Stem Cells
[Watch the Video] This is one of many newsclips describing the discovery of pluripotent stem cells from the menstrual blood in a recent publication by the adult stem cell company Medistem (mdsm.ob).Sunday November 18th, 2007 @ 12:19:20 EST
Allogeneic Serum is OK for Mesenchymal Stem Cell Culture
Stockholm, Sweden - The use of mesenchymal stem cells as a therapeutic is now a clinical reality. US companies such as Osiris Therapeutics are in Phase III of clinical trials, whereas clinics outside of the US such as Cellmedicine are offering such therapies as a fee for service. One of the problems with growing stem cells has always been the issue of fetal calf serum. Generally, cell...Sunday November 11th, 2007 @ 16:14:31 EST
Latvian Stem Cell Meeting Success
The University of Latvia hosted an international conference entitled “Stem Cells and Cell Therapy” on November 2nd, 2007. StemCellPatents.com sent a representative to observe the meeting. Meeting organizer Dr Janis Ancans provided an overview of the state of the art in stem cell research, followed by data describing characterization of dermal, adipose, and bone marrow derived stem cell...Sunday November 4th, 2007 @ 03:07:39 EST
Mesenchymal Stem Cells Talk with Hepatic Stellate Cells
Boston, MA - The ability of stem cells to inhibit progression of liver disease has been demonstrated in pilot human clinical trials. However the mechanisms by which bone marrow stem cell populations mediate antifibrotic effects are not completely known. In the mentioned clinical trial, administration of intravenous autologous bone...Monday October 29th, 2007 @ 19:30:13 EST
TLR3 and 4 Ligation Abrogates Mesenchymal Stem Cell Immune Suppression
Florence, Italy - Mesenchymal stem cells are known to suppress immune responses in antigen specific and non-specific ways. In a recent paper (Liotta et al. TLR3 and TLR4 are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells And Can Inhibit Their T-cell...Monday October 29th, 2007 @ 02:53:33 EST
Wnt/beta catenin in regenerating liver ! stem cells everywhere !
Pittsburgh, PA - The Wnt pathway is involved in tissue morphogenesis and has been found activated in various stem cell types and cancers. In a recent paper (Apte et al. Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology. 2007 Oct 10) it was demonstrated that this pathway is activated in adult liver stem cells (oval cells) after liver damage. To induce liver...Friday October 26th, 2007 @ 19:26:50 EST
Telomerase important in epidermal stem cells
Madrid, Spain - Shortening of telomeres is associated with cellular senescence. However, the shortening of telomeres is known to be associated not just with cell death but also dysfunction. For example, associations have been previously made between hypertension and telomere shortening (Fuster et al. Telomere dysfunction in hypertension. J Hypertens. 2007 Nov;25(11):2185-2192). In a recent...Thursday October 25th, 2007 @ 00:18:01 EST
Sheep with bad kidneys: intra-renal arterial mesenchymal stem cell administration
Paris, France - Bone marrow derived mesenchymal stem cells are most likely going to be the first stem cell type approved in the US for regenerative, non-hematopoietic purposes. Currently the company Osiris Therapeutics is leading the way by performing pivotal Phase III trials using these cells. The use of mesenchymal stem cells for treatment of ischemic kidney injury was recently reported...Tuesday October 23rd, 2007 @ 22:56:48 EST